REPRINT: EV and pembrolizumab in collecting duct and renal medullary carcinoma
RCC Content Hub
Giuseppe Procopio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy, preliminary first-stage results from the Phase II REPRINT trial (NCT06302569), which evaluated enfortumab vedotin (EV) plus pembrolizumab in patients with rare, aggressive collecting duct carcinoma and renal medullary carcinoma. Antitumor activity was observed, with responses seen in a renal medullary carcinoma subtype and none in collecting duct carcinoma, and no severe adverse events. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.